Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Mar 15;24(12):2094-101.
doi: 10.1016/j.vaccine.2005.11.013. Epub 2005 Nov 21.

HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics

Peter A Newman  1 , Naihua Duan, Sung-Jae Lee, Ellen T Rudy, Danielle S Seiden, Lisa Kakinami, William E Cunningham
Affiliations

HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics

Peter A Newman et al. Vaccine. .

Abstract

HIV vaccines offer the best long-term hope of controlling the AIDS pandemic; yet, the advent of HIV vaccines will not ensure their acceptability. We conducted a cross-sectional survey (n=143), incorporating conjoint analysis, to assess HIV vaccine acceptability among participants recruited using multi-site (n=9), venue-based sampling in Los Angeles. We used a fractional factorial experimental design to construct eight hypothetical HIV vaccines, each with seven dichotomous attributes. The acceptability of each vaccine was assessed individually and then averaged across participants. Next, the impact of each attribute on vaccine acceptability was estimated for each participant using ANOVA and then analyzed across participants. Acceptability of the eight hypothetical HIV vaccines ranged from 33.2 (S.D. 34.9) to 82.2 (S.D. 31.3) on a 0-100 scale; mean=60.0 (S.D. 21.9). Efficacy had the greatest impact on acceptability (22.7; CI: 18.5-27.1; p<0.0001), followed by cross-clade protection (12.5; CI: 8.7-16.3, p<0.0001), side effects (11.5; CI: 7.4-15.5; p<0.0001), and duration of protection (6.1; CI: 3.2-9.0; p<.0001). Route of administration, number of doses and cost were not significant. Low acceptability of "partial efficacy" vaccines may present obstacles to future HIV vaccine dissemination. Educational and social marketing interventions may be necessary to ensure broad HIV vaccine uptake.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Two sample hypothetical HIV vaccines as presented to participants on separate laminated cards.
See this image and copyright information in PMC

References

    1. Cohen J. A setback and an advance on the AIDS vaccine front. Science. 2003;300(5616):28–9. - PubMed
    1. International AIDS Vaccine Initiative (IAVI) Report: ongoing trials of preventative HIV vaccines. [accessed 24.9.2004]. Aug 5 updated. http://www.iavireport.org/specials/OngoingTrialsofPreventiveHIVVaccines.pdf.
    1. Cohen J. Vaccine results lose significance under scrutiny. Science. 2003;299(5612):1495. - PubMed
    1. Vaxgen announces results of its phase III HIV vaccine trial in Thailand: Vaccine fails to meet endpoints. [accessed 24.9.2004]. http://www.vaxgen.com/pressroom/index.html.
    1. Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C, et al. Candidate HIV/AIDS vaccines: lessons learned from the world’s first phase III efficacy trials. AIDS. 2003;17(2):147–56. - PubMed

Publication types